Uni-Bio Science Group Ltd
00690
Company Profile
Business description
Uni-Bio Science Group Ltd is an investment holding company. It operates in three segments: Chemical pharmaceutical products, Biological pharmaceutical products, and Pipeline products. Its geographical segments are Hong Kong and China, of which all of its revenue comes from China. The company products include GeneSoft, GeneTime, Pinup, Boshutai, Bokangtai, and others. All of the company revenue is generated from PRC.
Contact
No. 20 Science Park East Avenue
Unit 502, 5th Floor, Hong Kong Science Park
Shatin, New Territories
Hong Kong
HKGT: +852 31023232
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
458
Stocks News & Analysis
stocks
Why we’ve downgraded this ASX software player
Morningstar lowers our fair value estimate for Megaport by 16% after mispricing leads to a downgrade in capital allocation rating.
stocks
The market hates this compelling ASX income play
Santos continues to trade at a valuation that implies no growth in the years ahead. Our analyst Mark Taylor thinks that is misguided.
stocks
Lessons from the top performing ASX share
Chasing performance can lead to poor results but investors can still learn from top performers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,717.10 | 18.00 | 0.21% |
| CAC 40 | 7,235.11 | 55.86 | 0.78% |
| DAX 40 | 19,626.45 | 200.72 | 1.03% |
| Dow JONES (US) | 44,910.65 | 188.59 | 0.42% |
| FTSE 100 | 8,287.30 | 6.08 | 0.07% |
| HKSE | 19,636.48 | 212.87 | 1.10% |
| NASDAQ | 19,218.17 | 157.69 | 0.83% |
| Nikkei 225 | 38,087.60 | 120.43 | -0.32% |
| NZX 50 Index | 13,091.99 | 25.07 | 0.19% |
| S&P 500 | 6,032.38 | 33.64 | 0.56% |
| S&P/ASX 200 | 8,457.10 | 20.90 | 0.25% |
| SSE Composite Index | 3,348.97 | 22.51 | 0.68% |